张田甜，女，博士，副教授，硕士生导师。2015年毕业于中山大学药事管理专业，获博士学位，哈佛公共卫生学院联合培养博士。2015年入职402永利集团官网。现任广东省药理学会药物经济学专业委员会副主任委员，广东省药学会药物经济学与卫生技术评估专业委员会常委兼副秘书长，中国医疗保健国际交流促进会循证医学分会委员，广东省卫生经济学会药物经济与临床评价专业委员会副主任委员。主持国家自然科学青年基金项目、广东省自然科学基金项目、广东省卫生厅医学科研基金及校级基金等多项课题；参与负责广州市医保局委托课题多项。近三年以（共）第一作者/通讯作者在《Hypertension》《Oral Oncology》等SCI杂志发表文章15篇。曾获2018全国高等学校临床药学专业青年教师教学能力大赛一等奖、2018全国高等学校临床药学专业微课大赛一等奖、永利集团全英教学比赛一等奖、新任教师教学竞赛特等奖。

研究方向

为药物经济学、卫生经济学、卫生技术评估。

主持科研项目：

Ø 主持国家自然科学基金青年项目《H型高血压精准健康管理策略的卫生经济学研究》（No.71704064）

Ø 主持广东省自然科学基金项目《基于证据-决策模型的超说明书用药评价体系研究：以系统性红斑狼疮治疗为例》（No. 32217064）

Ø 主持广东省医学科学基金项目《超说明书用药评价体系构建与应用》（No.B2016122）

Ø 主持永利集团科研培育与创新基金研究项目《超说明书用药评价体系构建与应用》

近三年代表性文章：

Ø Tiantian Zhang† , Tengfei Lin† , Yang Wang , Binyan Wang , Xianhui Qin , Feng Xie , Yimin Cui , Yong Huo , Xiaobin Wang , Zugui Zhang*, Jie Jiang*. Estimated stroke-free survival of folic acid therapy for hypertensive adults- projection based on the CSPPT. Hypertension, 2020;75:339–346 (IF=7.017)

Ø Peiyao Lu, Weiting Liang, Jiahao Li, Yanming Hong, Zhuojia Chen, Tao Liu, Pei Dong, Hongbing Huang*, Tiantian Zhang*, Jie Jiang*. A cost-effectiveness analysis: first-line avelumab plus axitinib vs sunitinib for advanced renal-cell carcinoma. Frontiers in pharmacology, Apr. 2020 (IF=3.845)

Ø Chen X, Liang W, Wan N, Zhang L, Yang Y, Jiang J, Zhang T*. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral oncology, 94 80-85. 2019 (IF=3.73)

Ø Zhu J, Zhang T, Li J, Lin J, Liang W, Huang W, Wan N, Jiang J. Association between Tumor Mutation Burden (TMB) and outcomes of cancer patients treated with PD-1/PD-L1 inhibitions: A meta-analysis. Frontiers in pharmacology, 10, 673. Jun.2019（Co-first author）(IF=3.845)

Ø Jiang X, Li J, Xie J, Liang Z, Wan N, Jiang J, Zhang T*, Wu Y*. Histamine2-receptor antagonists, proton pump inhibitors or potassium-competitive acid blocker preventing delayed bleeding after endoscopic submucosal dissection: a meta-analysis. Frontiers in pharmacology, Sep. 2019 (IF=3.845)

Ø Wan Ning, Zhang Tian-tian, Hua Si-Hua, Lu Zi-Luo, Ji Bo, Li Li-Xia, Lu Li-Qing, Huang Wen-Jie, Jiang Jie, Li Jian. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Cancer medicine,2020,9(5):（Co-first author）(IF=3.357)

Ø Wan N, Ji B, Li J, Jiang J, Yang C, Zhang T*, Huang W*. A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer. OncoTargets and therapy, 12, 4955. 2019  (IF=3.046)

Ø Tian-tian Zhang, Sen Wang, Ning Wan, Li Zhang, Zu-gui Zhang, Jie Jiang. Cost-effectiveness of Daratumumab based Triplet Therapies in Patients with Relapsed or Refractory Multiple Myeloma. Clinical Therapeutics, 40(7) 1122-1139. May 2018 (IF=2.935)

Ø Liang Z, Zhang T, Lin T, Liu L, Wang B, Fu A Z, Wang X, Xu X, Luo N, Jiang J. Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China. Quality of Life Research, 1-12. May 2019 （Co-first author）(IF=2.488)

Ø Qian D, Zhang T, Zheng P, Liang Z, Wang S, Xie J, Zhao L, Zhang Y, Situ B. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Therapy, 9(5), 1945-1958. Aug. 2018 （Co-first author）(IF=2.827)

Ø Xie J, Wan N, Liang Z, Zhang T*, Jiang J*. Ixazomib–the first oral proteasome inhibitor. Leukemia & lymphoma, 60(3) 610-618. 2019 (IF=2.674)

Ø Yaohua Cao, Ning Wan, Zhuoru Liang, Jingmei Xie, Sen Wang, Tengfei Lin, Tiantian Zhang*, Jie Jiang*. Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. Clinical lymphoma, myeloma & leukemia, 19(8) E478-E488. 2019 (IF=2.274)

Ø Yaohua Cao, Xin He, Lina Zhao, Yuwen He, Sen Wang, Tiantian Zhang*, Jie Jiang*. Efficacy and safety of Levetiracetam as adjunctive treatment in children with focal onset seizures: A systematic review and meta-analysis. Epilepsy research, 153 40-48. July 2019 (IF=2.178)

Ø Qian D, Zhang T, Tan X, Zheng P, Liang Z, Xie J, Jiang J, Situ B. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PloS one, 13(8), e0202563. Aug. 2018 （Co-first author）(IF=2.776)

Ø Zhang TT, Wang S, Lin T, Xie J, Zhao L, Liang Z, Li Y, Jiang J. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Oncotarget. 16; 8 (20):34001-34017. May 2017 (IF=5.037)

Ø Tiantian Zhang, Jianhong Tao, Jun Xu, Chuanbin Wu. Approvals of Pharmaceutical Drugs in China in the Post–Drug Registration Regulation II Era. Therapeutic Innovation & Regulatory Science.47(6) 692-698 November 2013 (IF=0.901)

Ø Jianhong Tao, Tiantian Zhang, Jun Xu, and Chuanbin Wu. Analysis of the Current Situation of Antibiotics Use in China: A Hospital-Based Perspective. Therapeutic Innovation & Regulatory Science. 47(1) 23-31. 2013（Co-first author）(IF=0.901)

联系电话：020-85222156

邮箱：zhangtiantian@jnu.edu.cn